Davita Inc vs Plby Group Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Plby Group Inc trades at $1 (market cap $118.21M). The key difference: Davita Inc is far larger — about 95.5× Plby Group Inc's market cap, and Davita Inc is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Plby Group Inc for 24 Days on average.
| DVA | PLBY | |
|---|---|---|
Market Cap | $11.29B | $118.21M |
Volume | 582,204 | 919,783 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $2.71 |
52-Week Low | $103.87 | $0.99 |
Typical Hold Time | 113 Days | 24 Days |
Enterprise Value | $24.01B | $263.80M |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
PLBY Group trades at $1.02, down 1.92% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue stabilizing around $120-125 million and net losses narrowing significantly from -$278 million in 2022 to -$13 million in 2025. Recent management appointments aim to drive brand growth, while positive operating cash flow in 2025 and projected profitability in 2026 signal potential turnaround.
While analyst consensus remains strongly bullish (75% buy ratings), the stock faces headwinds from high debt levels and negative shareholder equity. The path to sustainable profitability remains the key catalyst, with current valuation metrics suggesting cautious optimism if execution improves. Near-term price action appears range-bound near support levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →